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Future investigation is required to ﬁnd which modality (adjuvant 
chemotherapy vs. radiotherapy) needs to be given immediately after 
surgery for those with N2 disease and negative margin. 
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Accurate staging of the mediastinum in non-small cell lung cancer is 
essential to appropriately determine if patients should be candidates for 
surgical resection, neo-adjuvant therapy, or for deﬁnitive chemoradia-
tion. It has been shown that patients with persistent, bulky N2 disease 
following induction therapy have poor survival if they go on to surgery. 
Thus, re-staging patients after induction therapy is becoming even more 
important; however, the ideal method of staging the mediastinum is 
still under debate. With the continued development of new minimally 
invasive techniques, such as endobronchial ultrasound (EBUS) guided 
transbronchial needle biopsy and VATS staging, the question is sure to 
evolve.
Mediastinoscopy.
Cervical mediastinoscopy is the current gold standard for mediastinal 
staging. Pooling data from several studies, Toloza et al, found that 
cervical mediastinoscopy had a sensitivity of 81% and speciﬁcity 
approaching 100%; for a positive predictive value of 1.0 and nega-
tive predictive value of 0.91.1 In contrast, PET had an overall positive 
predictive value of 0.79 and negative predictive value of 0.93.2 The 
main risk with PET is that some patients with pathologically negative 
mediastinal disease may continue to have FDG-avid lymph nodes. 
Thus, some patients with potentially curable disease will be denied 
surgical intervention. Standard cervical mediastinoscopy is not able to 
sample aortopulmonary window, paraesophageal, and pulmonary liga-
ment nodes. Other drawbacks include the need for general anesthesia, 
the risk of bleeding, and risk of recurrent laryngeal nerve injury. 
Chamberlain Procedure and Video-Assisted Thoracic Surgery 
(VATS)
A left anterior parasternal mediastinotomy, or Chamberlain procedure, 
provides access to the subaortic space, however, generally requires 
division of costal cartilage. The sensitivity and speciﬁcity are 74% 
and 100% respectively. VATS also allows sampling of the AP window 
nodes. If performed at the time of deﬁnitive resection, an initial VATS 
sampling of ipsilateral mediastinal lymph nodes with frozen section 
may prevent the surgeon from going on to perform an unnecessary 
resection. There have been relatively little data comparing the accuracy 
of VATS staging to either PET or conventional mediastinoscopy. Like 
mediastinoscopy, these procedures require general anesthesia and carry 
a risk of bleeding.
Endoscopic and endobronchial ultrasound.
Endoscopic ultrasound guided ﬁne-needle aspiration (EUS-FNA) 
allows access to left sided paratracheal nodes, as well as para-aortic, 
subcarinal, para-esophageal, and sometimes inferior pulmonary liga-
ment nodes. For these lymph nodes, EUS-FNA has been shown to have 
comparable sensitivity and speciﬁcity to CT and PET. The diagnostic 
accuracy is further increased if there is lymph node enlargement. En-
dobronchial ultrasound (EBUS) is a relatively newer method of staging 
that uses an ultrasound transducer mounted on a videobronchoscope to 
guide FNA. It can be used to biopsy paratracheal, subcarinal, and peri-
bronchial nodes; in experienced hands, even some AP window nodes 
can be biopsied safely. In the few published case series, the sensitivity 
and speciﬁcity are roughly 85% and 100% respectively. Both EUS and 
EBUS can be done relatively quickly, without general anesthesia, and 
with a minimal complication rate. Combined, EUS and EBUS have the 
potential to accurately stage the entire mediastinum with low morbidity. 
Overview
The role for invasive staging of the mediastinum continues to evolve 
as new technologies emerge. Randomized trials comparing the newer 
methods with established methods are necessary. Although it is yet 
unclear which method or methods will become the new standard, all 
these invasive approaches have one distinct advantage over non-in-
vasive methods like CT or PET - access to tissue. For patients with 
mediastinal disease, these procedures can be used to make a deﬁni-
tive tissue diagnose at the same time as staging, which is required for 
initiation of induction therapy. In addition, as molecular proﬁling of 
tumors becomes more important, being able to analyze the biology of 
the tumor (both pre- and post-induction) may add another dimension to 
individually tailored treatment regimens. 
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Investigations of novel agents remain a cornerstone of clinical research 
in Oncology. Guidelines for investigations of novel agents have existed 
for many years. They include sequential investigations of a novel agent 
in the phase I, II and III setting. It is clear that the classical phase II 
study design is not particularly well suited to investigations of targeted 
agents since it may not result in measurable objective responses. Al-
ternative trial designs have been investigated over recent years. These 
include a randomized phase II trials as well as randomized discontinu-
ation trials and dose range trials. Examples of such studies and their 
impact on recent drug development will be presented. 
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A Medical Doctor studies for longer than most any other profession. 
The reason for this is that there is a considerable amount of knowledge 
required in order to be able to provide a correct diagnosis and cure 
to patients in his area of speciality. If diagnostic part of his activity is 
directly related to clinical practice (academic and/or private), the imple-
mentation of this activity requires a medically driven/controlled admin-
istrative organization. The dramatic improvement, technicality, cost and 
speciﬁcity of diagnostic procedures make the role of a single physician 
less and less predominant and the need for regulation more and more 
important. A medical input is necessary to determine which procedures 
are the most appropriate and should be available for all patients.
